Moreover, next-generation DC vaccines using the cDC2 (CD1c+/BDCA1+) subset have been proven safe and feasible, with promising clinical responses, indicating the ability of combined modality treatment in patients with advanced-stage metastatic prostate cancer and patients with stage IV metastatic melanoma [158,159]. Here, CD1C is linked to metastatic prostate carcinoma.